Abstract:Recently, Fiusa and colleagues [1] described that a high angiopoietin (Ang)-2/Ang-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Although this study failed to detect a statistically significant difference in the levels of vascular endothelial growth factor (VEGF) between both outcome groups, the observed increased Ang-2 concentrations and Ang-2/Ang-1 ratio in the febrile neutropenia subgroup of patients with septic shock address the concept that angiogenic factors could be a promising therapeutic target in sepsis. The imbalance of angiogenic factors and their receptors, including the Ang/Tie2 and VEGF/VEGF receptor pathways, has been shown to predict poor prognosis in sepsis and has been implicated as a contributing factor in multiple organ dysfunction. For these reasons, several strategies targeting Ang/Tie2 and VEGF/VEGF receptor are being explored in preclinical sepsis models; however, most of these agents are unavailable or not applicable in clinical practice. Efforts to develop anticancer agents that target angiogenesis have led to the approval of inhibitors of VEGF and its receptor, specifically bevacizumab. As recently reported in Critical Care, bevacizumab has proven effective in the treatment of sepsis in an animal model [2]. The current study reinforces and extends previous findings that Ang-2 levels are increased in the septic state and have been established as a prognostic biomarker for identification of the patient group with the highest mortality rates. Interestingly, most recently by using Ang-2 antibody treatment, Ziegler and colleagues [3] showed that inhibition of Ang-2 has a significant effect on survival of mice with sepsis. AMG 386 is an investigational peptide-Fc fusion protein that inhibits angiogenesis by preventing the interaction of Ang-1/2 with their receptor, Tie2. The human study demonstrated that intravenous AMG 386 appeared well tolerated, and its safety profile seemed to be distinct from that of VEGF axis inhibitors [4]; it has reached late stages of clinical development. This provides a basis for Ang-2 inhibition as a potential clinical-translational therapeutic target in sepsis. The distinct safety profiles of AMG 386 and the VEGF-axis inhibitors suggest that they could be combined to achieve cooperative action, which may thereby improve clinical efficacy without significant overlapping toxicities. Thus, recent findings indicate that angiogenic factors are potential therapeutic targets in sepsis. However, the safety profiles of these anti-angiogenic agents in septic patients are often complicated by organ dysfunction and may be different from those in cancer patients. Future clinical trials may be needed to evaluate the safety and efficacy of these anti-angiogenic agents in sepsis patients, either alone or in combination.

Amelioration of sepsis by TIE2 activation-induced vascular protection

Effect of Interleukin-36β on Activating Autophagy of CD4+CD25+ Regulatory T Cells and Its Immune Regulation in Sepsis.

Tie2 Activation Promotes Protection and Reconstitution of the Endothelial Glycocalyx in Human Sepsis

Role of Angiopoietin/Tie2 System in Sepsis: A Potential Therapeutic Target

Angiogenic Factors in Sepsis: Are We Ready for the New Therapeutic Era?

Procyanidin B2 Attenuates Sepsis-Induced Acute Lung Injury via Regulating Hippo/Rho/PI3K/NF-κB Signaling Pathway

Alpha-1 antitrypsin targeted neutrophil elastase protects against sepsis-induced inflammation and coagulation in mice via inhibiting neutrophil extracellular trap formation

Aloe-emodin plus TIENAM ameliorate cecal ligation and puncture-induced sepsis in mice by attenuating inflammation and modulating microbiota

S1PR3 agonism and S1P lyase inhibition rescue mice in the severe state of experimental sepsis

The Therapeutic Effect of an Anti-TNF-α/HSA/IL-6R Triple-Specific Fusion Protein Under Experimental Septic Conditions

Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines

Recombinant human thrombopoietin in alleviating endothelial cell injury in sepsis

ACE2 Rescues Sepsis-Associated Encephalopathy by Reducing Inflammation, Oxidative Stress, and Neuronal Apoptosis via the Nrf2/Sestrin2 Signaling Pathway

Modulating sphingosine 1-phosphate signaling with DOP or FTY720 alleviates vascular and immune defects in mouse sepsis

Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis

Casein Kinase 2 Alpha Inhibition Protects against Sepsis-Induced Acute Kidney Injury

Interferon-β alleviates sepsis by SIRT1-mediated blockage of endothelial glycocalyx shedding

Inhibiting Eph/ephrin signaling reduces vascular leak and endothelial cell dysfunction in mice with sepsis

Tanshinone IIA improves sepsis-induced acute lung injury through the ROCK2/NF-κB axis

A nanotrap improves survival in severe sepsis by attenuating hyperinflammation

Chemical chaperone TUDCA prevents apoptosis and improves survival during polymicrobial sepsis in mice